Our Pipeline

F I B R O S I S

IPF

RIPF

CKD

NASH

C N S

M E T A B O L I C

F I B R O S I S

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Idiopathic Pulmonary Fibrosis (IPF)

Radiation Induced Pulmonary Fibrosis (RIPF)

Chronic Kidney Disease (CKD)

Non-alcoholic steatohepatitis (NASH)

 

 

 

Androgenic Alopecia (AGA)

 

Alzheimer's Disease (AD)

 

 

Type 2 Diabetes (T2D)

 

 

COVID-19

D E R M A T O L O G Y

C N S

M E T A B O L I C

V I R A L

SAMiRNA™ platform technology

Delivery

Beyond the liver to the inflamed, adipogenic, neoplastic tissues

in organs via various RoA

Partnership

If you are interested in partnering with us for the clinical development and the commercialization of novel RNAi therapeutics using our proprietary SAMiRNA™ technology, please contact us at
collaborations@sirnagen.com or fill out a form below.

고리로

Partnership Inquiries

Submitted Successfully!